- Home
- / Prelude Therapeutics
Prelude Therapeutics
Total Funding
$122 M
Prelude Therapeutics Summary
Company Summary
- Overview
- Prelude Therapeutics is a biotechnology company that discovers and develops medicines targeting chromatin function to treat cancer and rare diseases. The company has developed a discovery program targeting protein arginine methyltransferase 5 (PRMT5), a member of the arginine methyltransferase family.
- Type
- Private
- Status
- Active
- Founded
- 2016
- HQ
- Wilmington, DE, US | view all locations
- Website
- https://preludetx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kris Vaddi, Founder, Chief Executive Officer and Director
Andrew Combs, Executive Vice President and Head of Chemistry
Madhu Pudipeddi, Senior Vice President of Technical Operations
LocationsView all
2 locations detected
Wilmington, DE HQ
United States
200 Powder Mill Rd
Canton, MA
United States
150 Royall St